Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2015 | Volume: 11 | Issue: 3 | Page No.: 226-235
DOI: 10.3923/ijp.2015.226.235
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Antidiabetic and Hypolipidemic Potential of 3, 4-dihydroisoquinolin-2(1H)- Sulfonamide in Alloxan Induced Diabetic Rats

H. Berredjem, Y. Reggami, M. Benlaifa, M. Berredjem and N. Bouzerna

Abstract:
The present study aimed to investigate the effects of the 3, 4-dihydroisoquinolin-2(1H)-sulfonamide on blood glucose, lipid profile, hepatic and renal functions and enzyme activities in alloxan-induced diabetic Wistar rats. Experimental diabetes was produced by a single intraperitoneal injection of alloxan (140 mg kg-1 b.wt.). Three groups of diabetic rats were administered orally with two doses of the novel sulfonamide (2.5 and 5 mg kg-1 b.wt.) and a standard drug, glibenclamide (2.5 mg kg-1 b.wt.), for 10 days. Changes in body weight, food consumption, water intake and blood glucose levels were recorded regularly. At the end of the treatment period, blood was collected to determine biochemical parameters and enzyme activities in serum samples. Pancreas, liver, kidneys, spleen and heart were weighed in order to evaluate the relative organ weight. Histological changes in pancreas were examined by microscopy according to procedure with hematoxylin-eosin. The treatment with 2.5 and 5 mg kg-1 of the tested compound decreased the pathophysiological disturbances of diabetic syndrome. A significant (p<0.001) anti-hyperglycemic activity was clearly observed from the 4th day. Significant decreases (p<0.05) in total lipid and total cholesterol levels and highly significant decreases (p<0.001) in the level of Triglyceride were also noted with the two doses of the tested compound. Moreover, renal and hepatic functions were improved and lesions of pancreas were reversed in treated animals. However, the tested compound at 5 mg kg-1 produced highly significant increase (p<0.001) in the relative spleen weight. Our findings suggest that the 3, 4-dihydroisoquinolin-2(1H)-sulfonamide is endowed with an interesting anti-diabetic activity comparable to glibenclamide; however, it could present an immunological risk, so further more studies must be undertaken.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

H. Berredjem, Y. Reggami, M. Benlaifa, M. Berredjem and N. Bouzerna, 2015. Antidiabetic and Hypolipidemic Potential of 3, 4-dihydroisoquinolin-2(1H)- Sulfonamide in Alloxan Induced Diabetic Rats. International Journal of Pharmacology, 11: 226-235.

DOI: 10.3923/ijp.2015.226.235

URL: https://scialert.net/abstract/?doi=ijp.2015.226.235

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom